Innovatus Life Sciences Acquisition Corp.

Innovatus Life Sciences Acquisition Corp. (ticker: ILAC) filed its S-1 registration statement with the SEC on April 6, 2021, seeking to identify and complete a business combination in the life sciences and healthcare sector. The blank-check company is sponsored by Innovatus Capital Partners, a healthcare-focused investment firm with experience across credit and equity strategies in the sector. ILAC completed its IPO in 2021, joining a large cohort of sector-specific vehicles that year targeting biotechnology, medical devices, and adjacent subsectors. The company was incorporated in Delaware and operated under standard SPAC governance frameworks common to life sciences-focused vehicles of that vintage. For full filing history, deal status, and analytical data on ILAC, sign up for complete access at SpacDesk.